[Anti-prostate cancer activity of Survivin-T34A mutant in vitro and in vivo].
OBJECTIVE
To investigate the effect of Survivin-T34A mutant on murine prostate cancer and its apoptosis-inducing efficacy in vivo and in vitro.


METHODS
In vitro, prostate cancer cells TRAMP-C1 were transfected with Survivin-T34A plasmid encapsulated by cationic liposome. The apoptosis of TRAMP-C1 was evaluated with flow cytometry. C57BL/6 mice model with TRAMP-C1 prostate cancer was established. Twenty four male mice with TRAMP-C1 prostate cancers were divided randomly into three groups, which were intravenously injected with normal saline, empty vector PORF-9-null encapsulated by cationic liposome and Survivin-T34A plasmid encapsulated by cationic liposome respectively twice a week for eight doses. The size of tumors was measured and the tumor sections of each group were stained with TUNEL reagent for apoptosis detection.


RESULTS
An apoptotic index of 46% of TRAMP-C1 transfected with Survivin-T34A plasmid encapsulated by cationic liposome was observed. The tumor volume of Survivin-T34A group of C57BL/6 mice with TRAMP-C1 prostate cancer was far smaller than those in the control groups (P < 0.05) and the tumors treated with Survivin-T34A showed significant increase of apoptosis compared with those of control groups (P < 0.05).


CONCLUSIONS
Survivin-T34A mutant efficiently inhibits the growth of prostate cancer, which is based on the mechanism of Survivin-T34A mutant inducing apoptosis of tumor cells.
Pan
Li
L
State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Peng
Xing-Chen
XC
Yuan
Qing-Zhong
QZ
Leng
Fei
F
Yu
Dan-Dan
DD
Shan
Yan
Y
Li
Zhi-Yong
ZY
Wang
Chun-Ting
CT
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000627:therapeutic use; D045744:Cell Line, Tumor; D015316:Genetic Therapy / Q000379:methods*; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics* / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D050505:Mutant Proteins / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000628:therapy*; D011897:Random Allocation; D000077022:Survivin
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D050505:Mutant Proteins; D000077022:Survivin